Catalysts for Boehringer Ingelheim Corp
113 tracked
Jun 20, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 20, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 20, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Jun 20, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
May 18, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Mar 22, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Feb 6, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Feb 6, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 13, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 13, 2022
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 13, 2022
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 13, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 13, 2022
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 3, 2022
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Sep 1, 2022
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Mar 21, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 21, 2022
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 21, 2022
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Mar 21, 2022
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Mar 18, 2022
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Feb 24, 2022
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 15, 2021
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Aug 18, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Jun 11, 2021
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Jun 11, 2021
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→